Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful conscientiously but unsuccessfully to develop an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last several shares of mine. My first CytoDyn article, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire interview which I came away with an inadequate impression of the company.

Irony of irony, the bad impression of mine of the business has grown steadily, though the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the technology and connected intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) along with the very first new drug program approval ($5 million), and also royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and numerous therapies, it’s this individual treatment and a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its website (below) shows an energetic company with diverse interests albeit centered on leronlimab, multiple illness types, multiple delivering presentations and multiple publications.

Can all of it be smoke and mirrors? That’s a question I have been asking myself through the really start of my interest in this organization. Judging by way of the multiples of a huge number of several responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some might say cult stock. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *